FINWIRES · TerminalLIVE
FINWIRES

午间要闻:AMD第一季度财报和第二季度业绩指引均超出预期;英伟达与康宁达成多年商业和技术合作协议

By

-- 周三上午交易时段,美国三大股指均上涨超过1%,投资者对美伊即将达成结束战争的协议表示乐观。 公司新闻方面,AMD(Advanced Micro Devices)周二晚间公布了第一季度调整后每股收益为1.37美元,高于去年同期的0.96美元,也高于FactSet分析师一致预期的1.29美元。第一季度营收为102.5亿美元,高于去年同期的74.4亿美元,也高于FactSet一致预期的99亿美元。该公司预计第二季度营收为112亿美元,上下浮动3亿美元,高于FactSet一致预期的105.4亿美元。AMD股价在午盘前后上涨了17.7%。 英伟达(Nvidia,NVDA)和康宁(Corning,GLW)周三宣布,双方已达成一项多年商业和技术合作协议,旨在扩大美国先进光连接技术的制造规模,以支持人工智能基础设施建设。根据合作协议,康宁公司将把其在美国的光技术产能提高10倍,并将其在美国的光纤产能提高50%以上。康宁公司周三向美国证券交易委员会(SEC)提交的文件显示,为配合此次合作,该公司已向英伟达出售认股权证,允许英伟达以每股180美元的行权价格购买至多1500万股康宁普通股。康宁公司还表示,英伟达也获得了预付认股权证,允许英伟达以每股0.0001美元的行权价格购买至多300万股康宁普通股,总购买价格为5亿美元。英伟达股价上涨5.2%,康宁股价上涨13.8%。 优步科技(Uber Technologies,股票代码:UBER)周三公布了第一季度非GAAP每股收益,为0.72美元,高于去年同期的0.50美元,也高于FactSet预测的0.69美元。优步(Uber)第一季度营收为132亿美元,高于去年同期的115.3亿美元,也高于FactSet预期的132.8亿美元。优步预计第二季度非GAAP每股收益为0.78美元至0.82美元,高于FactSet预期的0.79美元。该公司预计第二季度总预订额为562.5亿美元至577.5亿美元,高于FactSet预期的561.7亿美元。优步股价上涨8.2%。 迪士尼(DIS)周三公布了第二财季调整后每股收益为1.57美元,高于去年同期的1.45美元,也高于FactSet预期的1.49美元。第二财季营收为251.7亿美元,高于去年同期的236.2亿美元,也高于FactSet预期的248.7亿美元。该公司表示,预计2026财年调整后每股收益增长约12%,不计入第53周的影响。迪士尼股价上涨超过6%。 IBM(IBM)周三表示,正与Oracle(ORCL)合作,将Watsonx的强大功能引入Oracle云基础设施(OCI),以期“提升企业多智能体、人工智能驱动的生产力和效率”。该公司表示,Watsonx Orchesstrate AI智能体产品将于7月在OCI上线。IBM股价下跌0.9%,而Oracle股价上涨1.9%。

Price: $416.71, Change: $+61.45, Percent Change: +17.30%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL